MedTrace Logo

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

NCT01506336 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-12-11

No results posted yet for this study

Summary

The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.

Conditions

  • Gastro Intestinal Stromal Tumor

Interventions

DRUG

masitinib

masitinib 12 mg/kg/day

DRUG

sunitinib

sunitinib 50 mg/day

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Axel Le Cesne, MD · Institut Gustave Roussy, Villejuif, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-09-30
Completion
2012-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506336 on ClinicalTrials.gov